Dublin, Nov. 22, 2018 (GLOBE NEWSWIRE) -- The "CRISPR Technology Market by Product, Service, Application, End User - Global Forecast to 2023" report has been added to *ResearchAndMarkets.com's* offering.The CRISPR technology market is expected to grow from USD 562 million in 2018 to USD 1,715 million by 2023, at a CAGR of 25% during the forecast period.The CRISPR technology market is driven by various factors such as increasing funding and private investments and the growing adoption of CRISPR technology. However, the presence of alternate technologies can hinder the growth of the market.
*The CRISPR services segment is expected to grow at the highest CAGR during the forecast period.*
The CRISPR services segment is the faster-growing segment in the CRISPR technology market, by product and service. Based on services, the CRISPR services market is segmented into gRNA design and vector construction, cell line engineering, screening services, and other CRISPR services (mediated transcriptome editing and epigenome editing services). The cell line engineering services segment is expected to grow at the highest rate.
*The biomedical applications segment, by application, is projected to hold the largest market share during the forecast period.*
The major biomedical applications of CRISPR include gene therapy, drug discovery, and diagnostics. Across the globe, various gene therapy clinical trials are currently underway. These factors are expected to drive the adoption of CRISPR technology in this segment. In drug discovery applications, CRISPR is used to develop more physiologically relevant models (cell lines and animal models) that correlate better to the clinical setting and thereby reduce drug candidate failure in the initial steps. The ability of CRISPR to modify endogenous genes can help study the effect of drugs on targets along with endogenous proteins, rather than having to rely on overexpression.
*Asia Pacific is expected to record the highest growth rate during the forecast period.*
Currently, 144 gene and cell therapy companies are based in the APAC that can potentially use CRISPR technology in the coming future. In China, gene editing using CRISPR has attracted strong government funding. China was among the first to allow the editing of human embryos using CRISPR-Cas9, while the US and European countries banned it. As reported by Goldman Sachs, by the end of February 2018, China had registered nine clinical trials based on CRISPR-edited cells on various diseases such as cancers and HIV infection, whereas the US had registered only one trial since the beginning of 2018.Some of the key players of CRISPR in this region are Cellecta, Inc. (US), Thermo Fisher (US), GeneCopoeia, Inc. (US), Applied StemCell (US), Synthego Corporation (US), OriGene Technologies (US), Horizon Discovery (UK), Merck (Germany), and GenScript (US).*Recent Developments:*
· In March 2018, Danaher acquired Integrated DNA Technologies to expand its genomics portfolio.
· In September 2017, Horizon Discovery acquired Dharmacon, Inc. from GE Healthcare (US) for USD 85 million.
· Between 2017 and 2018, Merck has secured patents in Australia, Canada, Europe, Israel, Singapore, South Korea, and China, covering foundational CRISPR technology, for its in-house CRISPR technology.
*Key questions addressed by the report:*
· Who are the major market players in the CRISPR technology market?
· What are the regional growth trends and the largest revenue-generating regions for CRISPR technology?
· What are the major applications of CRISPR technology?
· Who are the major end users of CRISPR technology?
*Key Topics Covered:**1 Introduction*
*2 Research Methodology*
*3 Executive Summary*
*4 Premium Insights*
4.1 CRISPR Technology: Market Overview
4.2 Europe: CRISPR Technology Market, By End User and Country (2018)
4.3 CRISPR Technology Market, By Applications, 2018
*5 Market Overview*
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Availability of Government and Private Funding
5.2.1.2 Growing Adoption of CRISPR
5.2.2 Restraints
5.2.2.1 Off-Target Activity and the Presence of Alternative Technologies
5.2.3 Opportunities
5.2.3.1 Emerging Markets
5.2.4 Challenges
5.2.4.1 Ethical Issues
5.2.4.2 Lack of Standardized Regulations
5.2.4.3 Pending Patent Issues & Results of Clinical Trials
5.2.4.4 High Costs of Using CRISPR
5.2.4.5 Dearth of Trained Professionals
*6 CRISPR Technology Market, By Product & Service*
6.1 Introduction
6.2 CRISPR Products
6.2.1 Growing R&D Activities to Drive Market Growth
6.2.2 CRISPR Enzymes
6.2.2.1 Enzymes to Account for the Largest Share of the CRISPR Products Market
6.2.3 CRISPR Libraries
6.2.3.1 Growing Interest of Researchers in the Development of Novel Therapies is Driving the Adoption of CRISPR Libraries
6.2.4 CRISPR Kits
6.2.4.1 Growth in Awareness and Increase in Research Activities are Key Factors Driving Market Growth
6.2.5 Other CRISPR Products
6.3 CRISPR Services
6.3.1 CRISPR Services to Register the Highest Growth During the Forecast Period
6.3.2 gRNA Design & Vector Construction
6.3.2.1 gRNA Design and Vector Construction Segment to Dominate the CRISPR Services Market During the Forecast Period
6.3.3 Cell Line Engineering
6.3.3.1 Cell Line Engineering to Register the Highest Growth in the CRISPR Services Market During the Forecast Period
6.3.4 Screening Services
6.3.4.1 CRISPR Screening Services are Required for the Genome-Wide Interrogation of Gene Function
6.3.5 Other CRISPR Services
*7 CRISPR Technology Market, By Application*
7.1 Introduction
7.2 Biomedical Applications
7.2.1 Accelerated Progress in Gene Therapy, Drug Discovery, and Diagnostics Will Drive the CRISPR Technology Market
7.3 Agricultural Applications
7.3.1 Agricultural Accelerators Set Up in the Us, Europe, and APAC are Helping With the Commercialization of New Crops
7.4 Industrial Applications
7.4.1 Start-Ups in the US Have Been Taking Advantage of the CRISPR Technology for Industrial Applications
7.5 Biological Research
7.5.1 Proof-Of-Concept Studies Help in Developing New Applications of CRISPR That Can Be Commercialized
*8 CRISPR Technology Market, By End User*
8.1 Introduction
8.2 Pharmaceutical and Biopharmaceutical Companies
8.2.1 Success of Clinical Trials Will Play A Key Role in the CRISPR Technology Market for Pharma and Biopharma Companies
8.3 Biotechnology Companies
8.3.1 Rising Interest of Bioagricultural and Bioindustrial Companies in CRISPR to Spur Market Growth
8.4 Academic & Research Institutes
8.4.1 Research Funding and Collaborations With Commercial Organizations Will Drive Growth of This Segment
8.5 Contract Research Organizations
8.5.1 Adoption of CRISPR Technology By Contract Research Organizations Will Be Key Driving Factor
*9 CRISPR Technology Market, By Region*
9.1 Introduction
9.2 North America
9.2.1 US
9.2.1.1 Strong Scientific and Industrial Base Will Ensure Sustained Growth in the Years to Come
9.2.2 Canada
9.2.2.1 Changes in Regulations Will Generate Opportunities in the CRISPR Technology Market
9.3 Europe
9.3.1 UK and Ireland
9.3.1.1 High Activity in the Area of CRISPR and CRISPR-Based Research
9.3.2 Germany
9.3.2.1 Strong Base of Pharma Companies Will Favor the Growth of CRISPR
9.3.3 France
9.3.3.1 Growing Support and Funds for CRISPR Research to Support the French Market
9.3.4 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.1.1 China to Register the Highest Growth Rate in the APAC CRISPR Technology Market During the Forecast Period
9.4.2 Japan
9.4.2.1 Growing Collaborations Between Universities and Pharma/Biotech Companies to Drive Market Growth
9.4.3 South Korea
9.4.3.1 Strong Private Investments in CRISPR Technology Applications is the Major Factor Driving Market Growth in the Country
9.4.4 Rest of APAC
9.5 Rest of the World
*10 Competitive Landscape*
10.1 Market Overview
10.2 Market Ranking Analysis (2017)
10.3 Competitive Situation and Trends
10.3.1 Collaborations, Agreements, and Partnerships
10.3.2 Product Launches and Approvals
10.3.3 Acquisitions
10.3.4 Patent Approvals
10.3.5 Other Developments
*11 Company Profiles*· Agilent Technologies
· Cellecta, Inc.
· GeneCopoeia, Inc.
· GenScript
· Horizon Discovery Group
· Integrated DNA Technologies (IDT)
· Merck KGaA
· New England Biolabs
· Origene Technologies, Inc.
· Synthego Corporation
· Thermo Fisher Scientific
· Toolgen, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/2qdc4s/global_crispr?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics
Reported by GlobeNewswire 1 hour ago.
The breakdown specialist has only played a bit-part role in training this week but Eddie Jones claimed his fitness concerns were a bluff. Pocock was England's nemesis at the 2015 World Cup.
Reported by MailOnline 2 hours ago.
Manu Tuilagi has been compared to an 'excited kid' after being primed to make his first appearance of the autumn when England clash with Australia at Twickenham on Saturday.
Reported by MailOnline 2 hours ago.
This is how a Red Dead Redemption style armed robbery on horseback would look like in rural Australia.
Reported by eBaums World 2 hours ago.
Australia has revealed plans to increase government powers to strip citizenship from extremists and to control the movements of Australian fighters who return home from the battlefields of Syria and Iraq.Prime Minister Scott Morrison...
Reported by New Zealand Herald 2 hours ago.
It is the supreme request of many indigenous Australians - so can one state make history?
Reported by BBC News 2 hours ago.
Portions of jap Australia were coated via a mud typhoon so massive that it may be observed from house. The 300-mile typhoon has introduced a thick haze to landmarks such because the Sydney Opera Space, whilst the town’s 309m (1,014feet) tower has been slightly visual every now and then. Some flights on the town’s primary …
Reported by The News Articles 2 hours ago.
